Cargando…
Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies
Systemic toxicities have severely limited the clinical application of tumor necrosis factor (TNF) as an anticancer agent. Activity‐on‐Target cytokines (AcTakines) are a novel class of immunocytokines with improved therapeutic index. A TNF‐based AcTakine targeted to CD13 enables selective activation...
Autores principales: | Huyghe, Leander, Van Parys, Alexander, Cauwels, Anje, Van Lint, Sandra, De Munter, Stijn, Bultinck, Jennyfer, Zabeau, Lennart, Hostens, Jeroen, Goethals, An, Vanderroost, Nele, Verhee, Annick, Uzé, Gilles, Kley, Niko, Peelman, Frank, Vandekerckhove, Bart, Brouckaert, Peter, Tavernier, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709889/ https://www.ncbi.nlm.nih.gov/pubmed/31912630 http://dx.doi.org/10.15252/emmm.201911223 |
Ejemplares similares
-
Selective IL-1 activity on CD8(+) T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication
por: Van Den Eeckhout, Bram, et al.
Publicado: (2021) -
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state
por: Van Lint, Sandra, et al.
Publicado: (2023) -
Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE
por: Cauwels, Anje, et al.
Publicado: (2021) -
MAPK-activated protein kinase 2-deficiency causes hyperacute tumor necrosis factor-induced inflammatory shock
por: Vandendriessche, Benjamin, et al.
Publicado: (2014) -
Vaccines targeting the neovasculature of tumors
por: Matejuk, Agata, et al.
Publicado: (2011)